4D Molecular Therapeutics revealed positive Phase II data Wednesday for its wet age-related macular degeneration candidate at the American Society of Retina Specialists (ASRS) annual scientific meeting.
Tag Archive for: 4D Molecular Therapeutics
Topline results from a mid-stage study show that 4D Molecular Therapeutics’ investigational gene therapy cut annual rates of Eylea injections by 85% and 89% for the low and high doses, respectively.
The FDA put 4D Molecular Therapeutics’ gene therapy program, 4D-310, on clinical hold, the company announced February 2.